Chugai Pharma to Reduce Tamiflu Supply By Half This Winter (Japan)
This article was originally published in PharmAsia News
Chugai Pharmaceutical, the Japanese distributor of Tamiflu, has announced it will only supply the country with 6 million doses of the flu vaccine. That is only half of the 12 million doses the company supplied last year. The company says the cut is due to a report by the Japanese Health Ministry released in March. The report apparently advised against administering the drug to teenagers because of possible behavioral side effects. Although no concrete evidence of this connection has been found, Chugai announced that both teens and adults may shy away from the vaccine in light of the report. (Click here for more - May Require Paid Subscription
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.